Sirona Biochem Corp.’s annual general meeting was held at the offices of Sirona Biochem at Suite 1600, Room 16D, 595 Burrard St., Vancouver, B.C., on May 22, 2020, at 9 a.m. Pacific Time. All resolutions presented to the shareholders at the AGM were passed, as discussed in the meeting proxy materials published and mailed to the shareholders and posted at SEDAR.
Voting results:
- The number of directors of the company was set at five.
- All directors were elected with more than 96 per cent of votes in favour, being the following directors elected at the AGM: Howard J. Verrico, Christopher D. Hopton, Geraldine Deliencourt-Godefroy, Alex Marazzi and Jason Tian.
- The ordinary resolution to ratify and approve the stock option plan for continuation was passed by more than 97 per cent of votes in favour.
- The ordinary resolution to ratify and approve the shareholder rights plan agreement was passed by more than 97 per cent of votes in favour.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona Biochem’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona Biochem’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments.
We seek Safe Harbor.